Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
185.4 SEK | +5.70% | +4.51% | +38.67% |
Apr. 25 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Biotage AB Approves a Dividend, Payable on May 3, 2024 | CI |
Sales 2024 * | 2.13B 202M | Sales 2025 * | 2.39B 227M | Capitalization | 14.83B 1.41B |
---|---|---|---|---|---|
Net income 2024 * | 265M 25.18M | Net income 2025 * | 357M 33.92M | EV / Sales 2024 * | 6.75 x |
Net cash position 2024 * | 473M 44.94M | Net cash position 2025 * | 780M 74.06M | EV / Sales 2025 * | 5.89 x |
P/E ratio 2024 * |
56.2
x | P/E ratio 2025 * |
41.7
x | Employees | 669 |
Yield 2024 * |
0.93% | Yield 2025 * |
1.14% | Free-Float | 99.55% |
Latest transcript on Biotage AB
1 day | +5.70% | ||
1 week | +4.51% | ||
1 month | +10.36% | ||
3 months | +6.74% | ||
6 months | +41.53% | ||
Current year | +38.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | 06-02-08 | |
Andrew Kellett
DFI | Director of Finance/CFO | 56 | 23-09-24 |
Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | 06-02-08 | |
Åsa Hedin
BRD | Director/Board Member | 62 | 19-10-31 |
Kieran Murphy
CHM | Chairman | 61 | Jan. 03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 746 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 185.4 | +5.70% | 1,194,396 |
24-05-30 | 175.4 | +1.74% | 84,383 |
24-05-29 | 172.4 | -3.15% | 88,137 |
24-05-28 | 178 | -1.22% | 118,064 |
24-05-27 | 180.2 | +1.58% | 147,539 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.67% | 1.41B | |
-27.52% | 16.33B | |
-40.04% | 2.96B | |
+15.16% | 1.82B | |
-6.86% | 1.55B | |
-15.36% | 976M | |
-26.08% | 846M | |
+3.53% | 811M | |
-24.63% | 631M | |
+23.58% | 593M |
- Stock Market
- Equities
- BIOT Stock